Strong financial health — a perfect Piotroski score of 9 and free cash flow at 136% of net income — provides a quality foundation, but two consecutive recent earnings misses, downward estimate revisions, negative price momentum, and risk/reward geometry that falls below the minimum asymmetry threshold combine to make this an unfavorable near-term setup.
Thesis pillars
- Momentum Below Long Term Trend↑Improving
- Consecutive Earnings Misses→Stable
- Thin Unfavorable Entry Geometry↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 13, 2026
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis
Healthcare · Medical Devices
Sell if holding. Analyst target reached at $385.12 — A.R:R is negative (-2.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (2.8% away).
Bio-Rad Laboratories develops and sells instruments, reagents, and consumables across Life Science (40% of net sales) and Clinical Diagnostics (60% of net sales), with approximately 60% of net sales from international markets and Europe as the largest region. The company employs... Read more
Sell if holding. Analyst target reached at $385.12 — A.R:R is negative (-2.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (2.8% away). Chart setup: No clear chart pattern; technical signals are mixed. Score 4.9/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 6d<=7d. Suitability: moderate.
Recent developments
updated 2026-10-29Recent Developments — Bio-Rad Laboratories, Inc.
Latest news
- NEWS Bio-Rad Q1 2026 Earnings: EPS Misses Estimates Amid Revenue Data Gap - Core Business Growth - dars.gov.et — dars.gov.et negative
- NEWS Entera Bio Rebounds As Investors Balance Phase 3 Funding Against Dilution Risk - TradingView — TradingView neutral
- NEWS Bio Rad Laboratories Inc (BIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey — TradingKey neutral
- NEWS Instinct Bio Stock Slides After Hours: Here's What is Going on With BIOT - Benzinga — Benzinga negative
- NEWS Bio-Rad Laboratories Inc (BIO) Stock Up 4.6% but GF Value Says O - GuruFocus — GuruFocus positive
Generated 2026-10-29T11:14:31Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $385.12 — A.R:R is negative (-2.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (2.8% away). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $363.86. Score 4.9/10, moderate confidence.
Analyst target $284.75 reached (−26.1% from $385.12); no take-profit level is published. Prior stop was $363.86. Stop-loss: $363.86.
Analyst target reached - limited upside remaining; Near 52-week high (2.8% away); Earnings in 6 days (event risk).
Bio-Rad Laboratories, Inc. trades at a P/E of 48.8 (forward 39.5). TrendMatrix value score: 4.5/10. Verdict: Sell.
10 analysts cover BIO with a consensus score of 3.5/5. Average price target: $335.
What does Bio-Rad Laboratories, Inc. do?Bio-Rad Laboratories develops and sells instruments, reagents, and consumables across Life Science (40% of net sales)...
Bio-Rad Laboratories develops and sells instruments, reagents, and consumables across Life Science (40% of net sales) and Clinical Diagnostics (60% of net sales), with approximately 60% of net sales from international markets and Europe as the largest region. The company employs about 7,450 people in 37 countries and held a $5.7 billion Sartorius AG equity stake at December 31, 2025.